Fibroids

Key Points

  • Fibroids (leiomyomas) are benign solid tumors arising from uterine smooth muscle.
  • About half of affected patients may be asymptomatic, while others have substantial quality-of-life burden.
  • Common symptom clusters include heavy menstrual bleeding, pelvic pain/pressure, urinary and bowel symptoms, dyspareunia, and infertility.
  • Fibroid growth is hormonally responsive (estrogen/progesterone) and often slows or regresses after menopause.

Pathophysiology

Fibroids are benign uterine smooth-muscle tumors. They are hormonally responsive and tend to enlarge under endogenous estrogen/progesterone stimulation.

Clinical burden is heterogeneous. Many patients have no symptoms, but symptomatic disease can produce bleeding, pain, mass-effect urinary/bowel complaints, and reproductive challenges.

Fibroids are usually slow growing and frequently regress with menopause as ovarian hormone levels decline.

Classification

  • Asymptomatic fibroids: Incidentally identified, no current functional burden.
  • Symptomatic fibroids: Bleeding, pain, pressure, urinary/bowel, sexual, or fertility-related impacts.
  • Fertility-preserving pathway: Medical control plus myomectomy-focused planning.
  • Definitive pathway: Hysterectomy-based management when fertility is not desired and symptoms persist.

Nursing Assessment

NCLEX Focus

Prioritize symptom burden and fertility goals to guide treatment-pathway counseling.

  • Characterize bleeding burden, pelvic pain/pressure pattern, and cycle impact.
  • Assess urinary and bowel compression symptoms (frequency/retention, constipation).
  • Assess dyspareunia and psychosocial quality-of-life effects.
  • Clarify fertility priorities before discussing procedural options.
  • Note that exam palpation may be nondiagnostic; pelvic ultrasound is primary imaging confirmation.
  • Trend anemia-risk labs in heavy bleeding contexts (hemoglobin, hematocrit, ferritin).

Nursing Interventions

  • Provide education on benign nature, expected natural history, and symptom-monitoring plan.
  • Reinforce adherence to follow-up and individualized treatment planning.
  • Support shared decision-making by aligning options with bleeding severity and fertility goals.
  • Reinforce tiered management: hormonal options or LNG-IUD, nonhormonal tranexamic-acid pathway when appropriate, GnRH analog escalation, and procedure selection by goals.
  • Teach key safety limits for tranexamic acid (thromboembolic-risk contexts, including thrombosis/hypercoagulopathy history and selected combined-hormonal-use contexts).
  • Explain surgical options clearly: myomectomy (uterus preserving), uterine-artery embolization, and hysterectomy as definitive treatment.
  • Teach return precautions for escalating bleeding, severe pain, or new instability symptoms.

Fertility-Pathway Mismatch

Fibroid treatment decisions that do not account for reproductive goals can cause avoidable harm or unwanted loss of fertility options.

Pharmacology

Drug ClassExamplesKey Nursing Considerations
hormonal-therapyEstrogen-progestin and progestin-based pathwaysUsed in selected cases for bleeding-control support; hormonal contraceptives are used symptomatically and are not considered fibroid-growth stimulants in this source context.
levonorgestrel-intrauterine-systemProgestin-releasing intrauterine systemMay reduce heavy bleeding in symptomatic fibroid care when fertility planning and anatomy are appropriate.
tranexamic-acidOral tranexamic acidNonhormonal bleeding-reduction option; avoid in elevated thromboembolic-risk settings.
gnrh-analogsLeuprolide-class optionsCan shrink fibroids and are often used before planned surgery.

Clinical Judgment Application

Clinical Scenario

A patient reports progressively heavier periods, pelvic pressure, and urinary frequency that now interfere with work and sleep.

  • Recognize Cues: Combined bleeding and mass-effect symptoms suggest symptomatic uterine fibroids.
  • Analyze Cues: Quality-of-life burden is significant and requires structured treatment planning.
  • Prioritize Hypotheses: Stabilize bleeding burden and identify best long-term option based on fertility goals.
  • Generate Solutions: Coordinate diagnostic confirmation and discuss medical versus procedural pathways.
  • Take Action: Implement symptom-control plan and expedited gynecologic follow-up.
  • Evaluate Outcomes: Symptoms improve and treatment selection aligns with patient priorities.

Self-Check

  1. Which symptom pattern best distinguishes asymptomatic from clinically significant fibroid disease?
  2. How do reproductive goals change fibroid treatment selection?
  3. Why can symptoms improve after menopause in many fibroid cases?